Kurbegov Named Vice President and Physician-in-Chief of Clinical Programs at Sarah Cannon

Article

Dax Kurbegov, MD, was named vice president and physician-in-chief of clinical programs at Sarah Cannon in Nashville, Tennessee. He will oversee the expansion of Sarah Cannon’s cancer network, which sees more than 120,000 newly diagnosed cancer cases per year.

Dax Kurbegov, MD

Dax Kurbegov, MD

Dax Kurbegov, MD, was named vice president and physician-in-chief of clinical programs at Sarah Cannon in Nashville, Tennessee. He will oversee the expansion of Sarah Cannon’s cancer network, which sees more than 120,000 newly diagnosed cancer cases per year.

In his role, which began in April, Kurbegov will be responsible for unifying care standards across Sarah Cannon’s network, including 75 American College of Surgeons Commission on Cancer accredited hospitals, as well as dozens of accredited programs from the National Accreditation Program for Breast Centers, American College of Radiology, and Foundation for the Accreditation of Cellular Therapy, according to a press release from Sarah Cannon. He will work with divisional operations teams and tumor-specific workgroups across the organization for strategic development, implementation, and evaluation of programs and services.

“Sarah Cannon is a global leader in cancer research and care, providing state-of-the-art cancer care for patients in their communities,” Kurbegov said. “I look forward to working with the team of expert physicians and leaders to standardize the implementation of the latest treatments into care delivery to improve outcomes for patients across the US.”

Kurbegov was previously the physician vice president of the national oncology service line for Catholic Health Initiatives’ (CHI) 50 cancer centers across the US, which involved leading program development and standardization of clinical processes across tumor sites for national oncology programs, with a special focus on strategic initiatives to improve patient outcomes. While at the CHI he successfully led CHI’s application to the National Cancer Institute Community Oncology Research Program and served as the vice president of clinical research.

Kurbegov received his bachelor of science degree from Stanford University and his medical degree from Baylor College of Medicine. He completed his internship and residency in internal medicine at University of Colorado Health Sciences Center and his medical oncology fellowship at The University of Texas MD Anderson Cancer Center.

“With Kurbegov’s expertise in developing comprehensive cancer services, we can accelerate the building of tumor site centers of excellence for our multidisciplinary programs,” said Howard A. "Skipp" Burris III, MD, of clinical operations and chief medical officer at Sarah Cannon. “His contributions will enhance our network of leading physicians and drive improved outcomes for our patients."

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content